Characteristics | n = 41 |
---|---|
Gender | |
Male | 29 (71%) |
Female | 12 (29%) |
Age (years) | |
Median (min-max) | 60 (33-82) |
ECOG | |
0/1 | 16/15 (98%) |
Symptoms-Clinical manifestations | |
Abdominal pain | 9 (22%) |
Constipation | 4 (10%) |
Rectal bleeding | 5 (12%) |
Accidental discovery | 9 (22%) |
Others (genito urinary, pelvic heaviness) | 6 (15%) |
Unknown | 8 (19%) |
Tumor characteristics | |
Tumor location | |
Rectum (Middle third/Lower third) | 9/22 (24/50%) |
Pararectal space | 7 (17%) |
Unspecified | 3 (9%) |
Tumor size (mm) | |
median (min-max) | 62 (6-130) |
Evaluated by: | |
Abdominopelvic CT Scan | 21 (51%) |
MRI | 18 (44%) |
Endosonography | 23 (56%) |
Unknown | 6 (14%) |
Histology/Genotype/risk | |
CD117+ | 34 (83%) |
CD34+ | |
Mitotic index | |
≤ 5/50 HPF | 11 (27%) |
> 5/50 HPF | 21 (51%) |
Unknown | 9 (22%) |
Mutation status (done on 12 cases) | KIT Exon 11 mutation in 10/12 |
KIT Exon 9 mutation in 1/12 | |
KIT Exon 17 mutation in 1/12 | |
None PDGFRA mutation | |
NIH risk categories | |
Very low risk | 3 (7%) |
Low risk | 3 (7%) |
Intermediate risk | 6 (14%) |
High risk | 18 (42%) |
Miettinen risk categories | |
None risk | 3 (7%) |
Low risk | 4 (10%) |
High risk | 23 (56%) |
Insufficient data (unclassified) | 11 (26%) |